Real-world demographic and clinical profiles of patients with treatment-resistant depression initiated on esketamine nasal spray.
Ludovic Samalin, Lila Mekaoui, Pierre De Maricourt, Anne Sauvaget, Marie-Alix Codet, Émeline Gaudré-Wattinne, Clotilde Wicart, Maud Rothärmel
International Journal of Psychiatry in Clinical Practice June 1, 2024 DOI: 10.1080/13651501.2024.2398788 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Observational study Peer reviewed |
|---|---|
| Sample size | 157 |
| Population | Adults with treatment-resistant depression |
| Intervention | Esketamine |
| Topics | Depression Esketamine |
| Keywords | Clinical profile Real-world experience Mood disorder therapy Intranasal antidepressant Trd Clinical outcomes patient |
| Citations | 3 |
| Key findings | Esketamine is used in treatment-resistant depression regardless of disease severity, subtype, or comorbidities, and its earlier use in later cohorts suggests growing clinical familiarity and access. |
Abstract
ESKALE is a French, multicentre, observational study of adults with treatment-resistant depression (TRD) treated with esketamine. This interim analysis describes baseline demographic and clinical characteristic evolution in patients included and treated from early access program to post-marketing launch. Data were collected from medical records and included patient characteristics, disease history at esketamine initiation, use of neurostimulation, the patient's care pathway, and the number of antidepressant treatment lines prescribed prior to esketamine initiation. Descriptive statistics were used for each cohort: the early access program 'Temporary Authorisation for Use' (ATU), post-ATU, and post-launch cohorts. The overall ESKALE cohort (N = 160 included; n = 157 treated with esketamine; average age 49.0 years; 66.2% female) demonstrated moderate-to-severe depression according to clinical assessment and a mean Montgomery-Åsberg Depression Rating Scale score of 32.6 (8.0); however, severity, subtype, and comorbidities were heterogeneous across the cohorts. Earlier use of esketamine and prior to alternative treatments occurred during the later cohorts. These findings demonstrated a high burden of TRD in these patients and that esketamine is used in TRD treatment regardless of their disease severity, subtype, or existing comorbidities. These results also suggest that esketamine is potentially a clinically useful alternative treatment, particularly with healthcare professionals gaining greater familiarity with and easier access to esketamine.
Comparable studies
Other observational and cohort studies on esketamine for depression, most cited first.
Citations in the library
Cites 5
- Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study American Journal of Psychiatry May 21, 2019
- Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression JAMA Psychiatry June 5, 2019
- Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1) The International Journal of Neuropsychopharmacology July 9, 2019
- Management of Treatment-Resistant Depression: Challenges and Strategies Neuropsychiatric Disease and Treatment 2020
- Esketamine nasal spray in patients with treatment-resistant depression: the real-world experience in the French cohort early-access programme. International Journal of Psychiatry in Clinical Practice November 2022